Logo image of GLUE

MONTE ROSA THERAPEUTICS INC (GLUE) Stock Fundamental Analysis

NASDAQ:GLUE - Nasdaq - US61225M1027 - Common Stock - Currency: USD

4.38  +0.15 (+3.55%)

After market: 4.38 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to GLUE. GLUE was compared to 551 industry peers in the Biotechnology industry. The financial health of GLUE is average, but there are quite some concerns on its profitability. GLUE is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year GLUE was profitable.
GLUE had a positive operating cash flow in the past year.
In the past 5 years GLUE always reported negative net income.
GLUE had negative operating cash flow in 4 of the past 5 years.
GLUE Yearly Net Income VS EBIT VS OCF VS FCFGLUE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

GLUE has a better Return On Assets (1.56%) than 90.74% of its industry peers.
The Return On Equity of GLUE (2.24%) is better than 91.83% of its industry peers.
Industry RankSector Rank
ROA 1.56%
ROE 2.24%
ROIC N/A
ROA(3y)-30.94%
ROA(5y)-37.13%
ROE(3y)-49.37%
ROE(5y)-71.64%
ROIC(3y)N/A
ROIC(5y)N/A
GLUE Yearly ROA, ROE, ROICGLUE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

With an excellent Profit Margin value of 3.86%, GLUE belongs to the best of the industry, outperforming 91.65% of the companies in the same industry.
GLUE does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 3.86%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GLUE Yearly Profit, Operating, Gross MarginsGLUE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

More info and screens

6

2. Health

2.1 Basic Checks

GLUE does not have a ROIC to compare to the WACC, probably because it is not profitable.
GLUE has more shares outstanding than it did 1 year ago.
The number of shares outstanding for GLUE has been increased compared to 5 years ago.
GLUE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GLUE Yearly Shares OutstandingGLUE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
GLUE Yearly Total Debt VS Total AssetsGLUE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of 1.15, we must say that GLUE is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of GLUE (1.15) is better than 66.61% of its industry peers.
GLUE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 1.15
ROIC/WACCN/A
WACC11.13%
GLUE Yearly LT Debt VS Equity VS FCFGLUE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 5.61 indicates that GLUE has no problem at all paying its short term obligations.
With a Current ratio value of 5.61, GLUE perfoms like the industry average, outperforming 58.62% of the companies in the same industry.
GLUE has a Quick Ratio of 5.61. This indicates that GLUE is financially healthy and has no problem in meeting its short term obligations.
GLUE has a Quick ratio of 5.61. This is comparable to the rest of the industry: GLUE outperforms 59.71% of its industry peers.
Industry RankSector Rank
Current Ratio 5.61
Quick Ratio 5.61
GLUE Yearly Current Assets VS Current LiabilitesGLUE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 115.63% over the past year.
EPS 1Y (TTM)115.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%393.93%

3.2 Future

The Earnings Per Share is expected to decrease by -8.21% on average over the next years.
Based on estimates for the next years, GLUE will show a very strong growth in Revenue. The Revenue will grow by 22.64% on average per year.
EPS Next Y43.71%
EPS Next 2Y-20%
EPS Next 3Y-12.74%
EPS Next 5Y-8.21%
Revenue Next Year330.64%
Revenue Next 2Y30.81%
Revenue Next 3Y28.85%
Revenue Next 5Y22.64%

3.3 Evolution

GLUE Yearly Revenue VS EstimatesGLUE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
GLUE Yearly EPS VS EstimatesGLUE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 12.51 indicates a correct valuation of GLUE.
95.64% of the companies in the same industry are more expensive than GLUE, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of GLUE to the average of the S&P500 Index (26.48), we can say GLUE is valued rather cheaply.
GLUE is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 12.51
Fwd PE N/A
GLUE Price Earnings VS Forward Price EarningsGLUE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

GLUE's Price/Free Cash Flow ratio is rather cheap when compared to the industry. GLUE is cheaper than 98.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.84
EV/EBITDA -51.02
GLUE Per share dataGLUE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
GLUE's earnings are expected to decrease with -12.74% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.29
PEG (5Y)N/A
EPS Next 2Y-20%
EPS Next 3Y-12.74%

More info and screens

0

5. Dividend

5.1 Amount

GLUE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MONTE ROSA THERAPEUTICS INC

NASDAQ:GLUE (8/8/2025, 8:00:00 PM)

After market: 4.38 0 (0%)

4.38

+0.15 (+3.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners101.37%
Inst Owner Change0.41%
Ins Owners0.85%
Ins Owner Change0.06%
Market Cap269.41M
Analysts84
Price Target16.61 (279.22%)
Short Float %14.63%
Short Ratio19.68
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)671.65%
Min EPS beat(2)262.91%
Max EPS beat(2)1080.39%
EPS beat(4)4
Avg EPS beat(4)351.7%
Min EPS beat(4)21.93%
Max EPS beat(4)1080.39%
EPS beat(8)7
Avg EPS beat(8)168.99%
EPS beat(12)10
Avg EPS beat(12)113.41%
EPS beat(16)12
Avg EPS beat(16)31.41%
Revenue beat(2)2
Avg Revenue beat(2)433.62%
Min Revenue beat(2)422.32%
Max Revenue beat(2)444.91%
Revenue beat(4)4
Avg Revenue beat(4)338.3%
Min Revenue beat(4)241.21%
Max Revenue beat(4)444.91%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.56%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7.49%
EPS NY rev (1m)0%
EPS NY rev (3m)62.38%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-24.21%
Revenue NY rev (1m)0%
Revenue NY rev (3m)66.76%
Valuation
Industry RankSector Rank
PE 12.51
Fwd PE N/A
P/S 1.69
P/FCF 8.84
P/OCF 7.77
P/B 0.98
P/tB 0.98
EV/EBITDA -51.02
EPS(TTM)0.35
EY7.99%
EPS(NY)-1.47
Fwd EYN/A
FCF(TTM)0.5
FCFY11.31%
OCF(TTM)0.56
OCFY12.87%
SpS2.59
BVpS4.47
TBVpS4.47
PEG (NY)0.29
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.56%
ROE 2.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 3.86%
GM N/A
FCFM 19.11%
ROA(3y)-30.94%
ROA(5y)-37.13%
ROE(3y)-49.37%
ROE(5y)-71.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 50.66%
Cap/Sales 2.63%
Interest Coverage N/A
Cash Conversion 564.37%
Profit Quality 495.34%
Current Ratio 5.61
Quick Ratio 5.61
Altman-Z 1.15
F-Score8
WACC11.13%
ROIC/WACCN/A
Cap/Depr(3y)233.13%
Cap/Depr(5y)356.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)115.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.12%
EPS Next Y43.71%
EPS Next 2Y-20%
EPS Next 3Y-12.74%
EPS Next 5Y-8.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%393.93%
Revenue Next Year330.64%
Revenue Next 2Y30.81%
Revenue Next 3Y28.85%
Revenue Next 5Y22.64%
EBIT growth 1Y98.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.61%
EBIT Next 3Y8.63%
EBIT Next 5YN/A
FCF growth 1Y127.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y139.18%
OCF growth 3YN/A
OCF growth 5YN/A